Crystagen vs Thymulin
A side-by-side research comparison of Crystagen and Thymulin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Crystagen | Thymulin |
|---|---|---|
| Full name | Crystagen (Immune Peptide Bioregulator) | Thymulin (Facteur Thymique Serique) |
| Category | Immune Support | Immune Support |
| Status | Research compound (peptide bioregulator) | Research compound |
| Mechanism | As a signal peptide, it is proposed to enter cells and regulate gene expression in immune tissue, supporting normal thymic and lymphoid function, immune cell maturation, and balanced immune responses. | Binds to specific receptors on T-cell precursors promoting their differentiation into mature T-cells, modulates cytokine production, and requires zinc as cofactor. |
| Molecular weight | ~ (short peptide) | 847.9 Da |
| Half-life | Short (peptide) | ~2 hours |
| Bioavailability | Oral (encapsulated) or subcutaneous | ~80% subcutaneous |
| Typical dose | ~1-2 capsules/day or short injectable courses | 1-5 mg |
| Frequency | Once daily | 2-3x per week |
| Route | Oral capsule or subcutaneous | Subcutaneous injection |
Crystagen reported benefits
- Immune regulation support
- Thymic/lymphoid tissue support (proposed)
- Immune resilience
- Short course-based protocol
- Part of bioregulator longevity systems
Thymulin reported benefits
- T-cell maturation support
- Thymic function restoration
- Zinc-dependent immune activation
- Anti-inflammatory properties
Related comparisons
Research and educational reference only. Not medical advice.